Your browser doesn't support javascript.
loading
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial.
Wiegand, J; Wedemeyer, H; Franke, A; Rößler, S; Zeuzem, S; Teuber, G; Wächtler, M; Römmele, U; Ruf, B; Spengler, U; Trautwein, C; Bock, C T; Fiedler, G M; Thiery, J; Manns, M P; Brosteanu, O; Tillmann, H L.
Affiliation
  • Wiegand J; Universitätsklinikum Leipzig, Klinik für Gastroenterologie und Rheumatologie, Leipzig, Germany.
J Viral Hepat ; 21(10): 744-50, 2014 Oct.
Article in En | MEDLINE | ID: mdl-24329913
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Placebos / Lamivudine / Hepatitis B Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Aspects: Patient_preference Limits: Adult / Humans / Middle aged Language: En Journal: J Viral Hepat Journal subject: GASTROENTEROLOGIA Year: 2014 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Placebos / Lamivudine / Hepatitis B Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Aspects: Patient_preference Limits: Adult / Humans / Middle aged Language: En Journal: J Viral Hepat Journal subject: GASTROENTEROLOGIA Year: 2014 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido